Highlightll Pharma’s Hong Kong IPO Application Lapses; Core Asset TLL-018 Enters Phase III Pivotal Trials
NewTimeSpace News: As disclosed by HKEX, the Main Board listing application of Hangzhou Highlightll Pharmaceutical Co., Ltd., filed on December 4, 2025, has recently lapsed upon expiry of the six-month review period. CICC and CMB International served as joint sponsors at the time of filing. Its core asset TLL-018 is the world’s sole highly selective TYK2/JAK1 inhibitor, now undergoing two Phase III registrational trials in China for chronic spontaneous urticaria and rheumatoid arthritis.
NewTimeSpace News: According to official HKEX filings, Highlightll’s Hong Kong Main Board IPO application submitted on December 4, 2025 has expired after the statutory six-month validity term, with CICC and CMB International appointed joint sponsors for the original submission.
Founded in 2017, Highlightll focuses on discovering and developing safe and effective therapeutics for patients suffering from autoimmune and inflammatory diseases globally. TLL-018, its lead candidate, is the world’s only highly selective TYK2/JAK1 inhibitor with potential to become a first-in-class and best-in-class treatment for chronic spontaneous urticaria and rheumatoid arthritis. Two Phase III registrational trials are ongoing in China, and the company targets NDA submission by the end of 2026.
Separately, self-developed TLL-041 is the world’s first and only brain-penetrant selective TYK2/JAK1 inhibitor indicated for neurodegenerative disorders. Its collaboration deal with Biohaven ranks as the largest disclosed transaction by total consideration in China’s neurodegenerative drug sector.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- Pengyang CSI Digital Economy Theme ETF (560800) rises 0.89%, aiming for a third consecutive gain
- Guotai CSI Coal ETF (515220) rises 1.29%, with a net inflow of 2.131 billion yuan for five consecutive days
- Harvest CSI Rare Earth Industry ETF (516150) falls 1.88%, with a scale increase of 6.268 billion yuan over the past year
- China Merchants CSI Animal Husbandry ETF (516670) falls 1.67%, with the latest net inflow of 14.9678 million yuan
- Hwabao WP CSI Subdivision Chemical Industry Theme ETF(516020) falls 2.26%, with the latest margin financing purchase amount reaching 4.0143 million yuan
